|
Investment in Macrophage Therapeutics, Inc. (Details) (USD $)
|
3 Months Ended | 1 Months Ended | |
|---|---|---|---|
|
Mar. 31, 2015
|
Mar. 31, 2014
|
Mar. 31, 2015
|
|
| Class of Stock [Line Items] | |||
| Derivative liabilities | $ 63,000us-gaap_DerivativeLiabilities | $ 63,000us-gaap_DerivativeLiabilities | |
| Deemed dividend on beneficial conversion feature of MT Preferred Stock | (46,000)navb_DividendPreferredStockDeemedDividendUponConversion | 0navb_DividendPreferredStockDeemedDividendUponConversion | |
| Minimum required proceeds from initial public offering | 50,000,000navb_PreferredConvertibleStockRighttoExchangeforCommonSharesMinimumRequiredProceedsfromInitialPublicOffering | ||
| Weighted average price per share | 80.00%navb_WeightedAveragePriceCommonStockPercentage | ||
| Convertible Preferred Stock | |||
| Class of Stock [Line Items] | |||
| Preferred stock authorized |
50us-gaap_PreferredStockSharesAuthorized / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
50us-gaap_PreferredStockSharesAuthorized / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
|
| Purchase price per share (USD per share) |
$ 50,000us-gaap_PreferredStockParOrStatedValuePerShare / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
$ 50,000us-gaap_PreferredStockParOrStatedValuePerShare / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
|
| Percentage of preferred stock reserved |
40.00%navb_ConvertiblePreferredStockPercentofSharesReserved / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
40.00%navb_ConvertiblePreferredStockPercentofSharesReserved / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
|
| Proceeds from issuance of convertible preferred stock and warrants |
500,000us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
||
| Deemed dividend on beneficial conversion feature of MT Preferred Stock |
46,000navb_DividendPreferredStockDeemedDividendUponConversion / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
||
| Value of warrants |
2,000,000navb_IssuanceofStockandWarrantsforPurchaseAgreementRemainingAmount / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
||
| Put option fair value |
113,000navb_DebtInstrumentFairValuePutOption / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
||
| Common stock value |
50,000navb_FutureCommonStockConversionDenominatorValue / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
50,000navb_FutureCommonStockConversionDenominatorValue / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
|
| Common Stock | |||
| Class of Stock [Line Items] | |||
| Price per share |
$ 3.00navb_FutureCommonStockConversionSharePrice / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
$ 3.00navb_FutureCommonStockConversionSharePrice / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
|
| Macrophage Therapeutics | Convertible Preferred Stock | |||
| Class of Stock [Line Items] | |||
| Preferred stock authorized |
50us-gaap_PreferredStockSharesAuthorized / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
50us-gaap_PreferredStockSharesAuthorized / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
|
| Preferred shares, per unit |
1navb_ConvertiblePreferredStockSharesIssuedUponConversionPerUnit / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
||
| Preferred stock issued |
10us-gaap_PreferredStockSharesIssued / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
10us-gaap_PreferredStockSharesIssued / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
|
| Deemed dividend on beneficial conversion feature of MT Preferred Stock |
$ 46,000navb_DividendPreferredStockDeemedDividendUponConversion / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
||
| Preferred stock value |
$ 58,320us-gaap_PreferredStockRedemptionPricePerShare / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
$ 58,320us-gaap_PreferredStockRedemptionPricePerShare / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_ConvertiblePreferredStockMember |
|
| Macrophage Therapeutics | Common Stock | |||
| Class of Stock [Line Items] | |||
| Shares authorized upon exercise of warrants |
1,500navb_CommonStockSharesAuthorizedUponExerciseofWarrants / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
1,500navb_CommonStockSharesAuthorizedUponExerciseofWarrants / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
|
| Common stock warrants, per unit |
30navb_CommonStockWarrantsIssuedUponConversionPerUnit / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
||
| Common stock as percentage of common equity |
1.00%navb_CommonStockasPercentageofCommonEquity / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
1.00%navb_CommonStockasPercentageofCommonEquity / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
|
| Number of shares underlying warrant issued |
300us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
300us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights / dei_LegalEntityAxis = navb_MacrophageTherapeuticsMember / us-gaap_StatementClassOfStockAxis = us-gaap_CommonStockMember |
|
| X | ||||||||||
|
- Definition
Common Stock as Percentage of Common Equity No definition available.
|
| X | ||||||||||
|
- Definition
Common Stock, Shares Authorized Upon Exercise of Warrants No definition available.
|
| X | ||||||||||
|
- Definition
Common Stock, Warrants, Issued Upon Conversion, Per Unit No definition available.
|
| X | ||||||||||
|
- Definition
Convertible Preferred Stock, Percent of Shares Reserved No definition available.
|
| X | ||||||||||
|
- Definition
Convertible Preferred Stock Shares, Issued Upon Conversion, Per Unit No definition available.
|
| X | ||||||||||
|
- Definition
Debt Instrument, Fair Value, Put Option No definition available.
|
| X | ||||||||||
|
- Definition
Dividend, Preferred Stock, Deemed Dividend Upon Conversion No definition available.
|
| X | ||||||||||
|
- Definition
Future Common Stock Conversion, Denominator Value No definition available.
|
| X | ||||||||||
|
- Definition
Future Common Stock Conversion, Share Price No definition available.
|
| X | ||||||||||
|
- Definition
Issuance of Stock and Warrants for Purchase Agreement, Remaining Amount No definition available.
|
| X | ||||||||||
|
- Definition
Preferred Convertible Stock, Right to Exchange for Common Shares, Minimum Required Proceeds from Initial Public Offering No definition available.
|
| X | ||||||||||
|
- Definition
Weighted Average Price, Common Stock, Percentage No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|